Navigation Links
Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study
Date:9/19/2011

NEW YORK, Sept. 19, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals (Nasdaq: KERX) today announced completion of patient enrollment in the long-term study component of its Phase 3 registration program of Zerenex™, the Company's ferric iron-based phosphate binder for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis. The Zerenex Phase 3 registration program, which is being conducted pursuant to a Special Protocol Assessment (SPA) with the Food and Drug Administration (FDA), is comprised of an already successfully-completed Phase 3 short-term study, and this ongoing Phase 3 long-term study.    

This Phase 3 long-term study is a multicenter, randomized, open-label, safety and efficacy clinical trial in over 400 ESRD patients on hemodialysis or peritoneal dialysis. The study consists of a 2-week washout period followed by a 52-week safety assessment in which patients are randomized 2:1 to receive either Zerenex or an active control. The 52-week safety assessment period is followed by a 4-week efficacy assessment.  During the 4-week efficacy assessment, only those patients randomized to treatment with Zerenex during the safety assessment period will be randomized in a 1:1 ratio to either continue treatment with Zerenex or to be switched to placebo for a 4-week period.

Dr. Julia Lewis, Professor of Medicine, Department of Nephrology, Vanderbilt University School of Medicine, and member of the Executive Committee of the Collaborative Study Group, is the Study Chair of the Zerenex Phase 3 registration program. Dr. Samuel S. Blumenthal, Professor of Medicine at Medical College of Wisconsin, is the study's Co-Principal Investigator.

Ron Bentsur, Chief Executive Officer of Keryx, commented, "We are pleased to have completed patient enrollment into the Zerenex Phase 3 long
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in KRX-0401 (Perifosine) Phase 3 Refractory Advanced Colorectal Cancer Study
2. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results
3. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2011 Financial Results
4. Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex™ Short-Term Phase 3 Study
5. Keryx Biopharmaceuticals to Present at 13th Annual BIO CEO and Investor Conference
6. Keryx Biopharmaceuticals to Present at 29th Annual J.P. Morgan Healthcare Conference
7. Keryx Biopharmaceuticals to Present at Lazard Capital Markets 7th Annual Healthcare Conference
8. Keryx Biopharmaceuticals to Present at the UBS 2010 Global Life Sciences Conference
9. Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer
10. Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstroms Macroglobulinemia
11. Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... , Kalifornien und HILDEN, Deutschland, May 26, ... Clinical Insight ®   ... und die Erstellung dazugehöriger Berichte; Vorstellung auf ... QIAGEN N.V. (NASDAQ: QGEN ... die Markteinführung von QIAGEN Clinical Insight ® ...
(Date:5/26/2015)... Inc. (NYSE: ALR ) (the "Company") announced today that, ... Quarterly Report on Form 10-Q for the three months ended ... notice from the New York Stock Exchange (the "NYSE") that ... listing requirements under the timely filing criteria established in Section ... The reason for the delay relates to Company,s need to ...
(Date:5/26/2015)... May 26, 2015   PDI , a ... announced that Oakwood Healthcare in Dearborn, ... winning entry in Delivering the Difference ... display excellence in building collaborative relationships between infection ... healthcare facilities.  Oakwood Healthcare,s infection ...
(Date:5/26/2015)... LOS ANGELES , 26. mája 2015 /PRNewswire/ ... ďakuje v mene svojej rodiny prezidentom Barackovi Obamovi ... vyjadrenú v súvislosti so stratou Dr. Rongxiang ... - http://photos.prnewswire.com/prnh/20150522/218111 Dr. Xu ... svojej dobe a jeho odhodlanie v oblasti vedy ...
Breaking Biology Technology:QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 2QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 3QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 4QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 5QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 6PDI Announces Winner in Delivering the Difference Contest 2PDI Announces Winner in Delivering the Difference Contest 3Dr. Rongxiang Xu, O legende 2
... (NYSE: WPI ), a leading specialty pharmaceutical,company, ... chief,executive officer, will provide an overview and update ... Global Pharmaceutical, Biotechnology and,Medical Device Conference on Tuesday, ... This presentation will be webcast live and ...
... 1 Inverness Medical,Innovations, Inc. (Amex: IMA ... release dated January 31, 2008 and entitled "Inverness ... Pharmaceutical,Biotechnology and Medical Device Conference on February 5, ... the Company,s presentation. The,correct time of the presentation ...
... the Highest Level of Clinical Immunology Expertise, ... Genetic,Immunity(R), a US/Hungarian clinical-stage biopharmaceutical company,focused on the ... announced that it has appointed,Richard B. Pollard, M.D. ... been a leader in HIV/AIDS research for more ...
Cached Biology Technology:Genetic Immunity Announces the Appointment of Richard B. Pollard, M.D. as Chief Medical Officer 2Genetic Immunity Announces the Appointment of Richard B. Pollard, M.D. as Chief Medical Officer 3
(Date:5/26/2015)... Research and Markets ( ... "Saudi Arabia Biometric Systems Market Forecast and ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The biometric systems market in ... to grow at over 22% CAGR through 2020 ... the surging demand for better biometric technologies in ...
(Date:5/25/2015)... SYDNEY , May 25, 2015  Australia,s market ... inception stage, although 2014 saw the advent of several ... on 24 April 2015 is expected to ignite interest ... devices in Australia . This in ... the industry and drive new partnerships amongst vendors and ...
(Date:5/22/2015)... 22, 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... be ending its promotional pricing and making the Wocket generally ... Laurence Savin , Head of Marketing said, "We,ve extended the ... the end of May. To get your wocket at this ... open the store on June 1, you,ll receive a unique ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market Forecast and Opportunities, 2020 with Morpho Safran, ZK Technlogy, and Suprema Dominating 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 4NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3
... handmade microscope in 1702, it was Anton van Leeuwenhoek who ... the rapid contraction of a stalk tethering the cell body ... a leaf. Little did van Leeuwenhoek imagine that more than ... set records for speed and power in the nano world ...
... his handmade microscope in 1702, it was Anton van Leeuwenhoek ... observed the rapid contraction of a stalk tethering the cell ... of a leaf. Little did van Leeuwenhoek imagine that more ... would set records for speed and power in the nano ...
... School of Medicine study in the December issue of Lancet ... with white blood cells as a major reason that cancer ... "Cancer cells exhibit a remarkable number of traits normally attributed ... to migrate to lymph nodes and distant organs and to ...
Cached Biology News:Similar Stem Cells In Insect And Human Gut 2Nano springs eternal; Protozoan 'engine' posts nano records 2New evidence supports century-old theory of cancer spread 2
... a DNA-dependent RNA polymerase which is stringently ... efficiently synthesizes in vitro transcripts from almost ... a T7 promoter. Transcripts can be ... vitro translation, substrates in RNA processing systems, ...
... fragment is a proteolytic product ... DNA Polymerase I which retains ... exonuclease activity, but has lost ... retains the polymerization fidelity of ...
... Source: E. coli strain containing an overproducing clone ... catalyzes the formation of a phosphodiester bond between ... duplex DNA or RNA. It repairs single-stranded nicks ... will join both blunt-end and cohesive-end fragments of ...
SHEEP ANTI BOVINE BETA-LACTOGLOBULIN A...
Biology Products: